The clinical relevance of this model is emphasized by the demonstration that concurrent elevation of PRMT5 and p53 arginine methylation occurs in primary human cancers such as mantle cell lymphoma and esophageal squamous cell carcinoma, two cancers where cyclin D1 is considered a driver oncogene. Here, CCND1 is linked to cancer.